A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 11 May 2016
At a glance
- Drugs Carotuximab (Primary) ; Everolimus; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 11 May 2016 According to a company media release, TRACON anticipates top-line data from this trial in 2017.
- 09 May 2016 According to a Tracon Pharmaceuticals media release, dosing has been initiated in this trial.